124 results about "Prognosis Marker" patented technology

The present invention relates to the identification of prognostic markers useful in determining the response of hepatitis c virus (HCV) infected patients to interferon alpha (IFN-α) treatment. The studies provide biomarkers that can be used to discern sustained responders and non-responders of IFN-α treatment. This information should enable treating physicians to help patients to make more informed decisions.

The invention discloses a prognosis marker for lung cancer, a method for anticipating lung cancer prognosis by using the marker and application of the marker. The marker comprises the following gene combinations: RP11-89K21.1, CDH17, GRIA1, CENPF, AP000438.2, HMMR, RP11-434D9.1, ADH1B, TPX2 and OR7E47P. The prognosis marker for lung cancer overcomes the defect that the difference between lung cancer treatment reaction and prognosis is big, resulting in inaccuracy and inconvenience in prognosis, and the prognosis marker for lung cancer rapidly, accurately and conveniently anticipates lung cancer prognosis through the marker and detection of the marker, realizes classification and stratification of high and low lung cancer hazards on the molecular level, and remarkably separates patients with high risk from patients with low risk, thereby guiding individualized treatment, having higher clinical application value and saving medical treatment cost.

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.

The present invention provides for the first time molecular diagnostic and prognostic markers for tongue cancer metastasis and extracapsular spread that are independent of histopathological evaluation.

The invention discloses a method for establishing a pancreatic cancer miRNA prognosis model and screening a targeted gene. The model comprises hsa-mir-424, hsa-mir-126, hsa-mir-3613 and hsa-mir-4772,nine key genes are identified, and the nine key genes comprise MMP14, ITGA2, THBS2, COL1A1, COL3A1, COL11A1, COL6A3, COL12A1 and COL5A2. According to the method for establishing the pancreatic cancermiRNA prognosis model, by means of TCGA and GEO databases, data is subjected to multi-step analysis through a plurality of R language installation packages and combines with clinical information, a Cox proportional risk regression model is established to search for prognosis biomarkers, the targeted gene of miRNA is predicted, the key genes related to pancreatic cancer are found out by utilizing Cytoscape, and related molecular functions and action mechanisms of the key genes are predicted through KEGG and GO analysis so as to search for new treatment targets and prognosis markers of pancreatic cancer patients.

The invention discloses a prognosis marker for the lung cancer and application thereof. The long chain non-coding RNA gene RP11-434D9.1 of the marker is quite related to the prognosis period of patients with the lung cancer, through the marker and expression for detecting the marker, lung cancer prognosis is rapidly, accurately and conveniently predicted, the grading and layering of lung cancer risks are realized according to molecular levels, and patients with different grades of risks are separated obviously. Through co-expression analysis, 238 genes related to the long chain non-coding RP1-434D9.1 are found out, through an enrichment analysis on GO and KEGG pathways of the 238 genes, the molecular functions of the long-chain non-coding RP1-434D9.1 are found out, and important biologicalexperiment clues are provided for improving prognosis molecular diagnosis of the patients with the lung cancer and related medicine targets.

A method for the identification of treatments and preventative agents for brain aging, subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and other degenerative dementias, the method including (a) the identification of the diagnosis and stage of the subject, (b) the identification of the duration of the stage of the condition and/or disorder, (c) the identification of prognostic markers based upon a formula incorporating the duration of the condition and/or stage, (d) the prospective separation of prognostic subgroups based upon outcome wherein the outcome is defined in these conditions as progression to a subsequent stage or stages, (e) the employment of a putative prognostic marker for an appropriate period of time, based upon the formula incorporating the duration of the condition and/or stage, (f) the application of in vivo, methodology specific techniques, in conjunction with stage specific prognostic subgroups, for the appropriate time period, for the identification, prospectively, of useful markers, (g) the employment of these markers to identify useful therapeutic agents for prevention and treatment.

The invention discloses a screening method and application of a plasma microRNA marker for identifying a gastric cancer. According to the screening method, cel-miR-39 serving as an external reference and miR-16 serving as an internal reference are used together, and data of to-be-tested microRNA are normalized, so as to improve the reliability of qRT-PCR data. On the basis of the method, plasma microRNA markers, namely miR-19b, miR-671-5p and miR-101, are screened, wherein the miR-19b and the miR-671-5p are used for distinguishing normal people from the patients with gastric cancer at different stages and different differentiated degrees, and can be used as the markers for gastric cancer screening; and especially the miR-671-5p is used for specifically distinguishing the patient with early gastric cancer from normal people. Therefore, the plasma microRNA markers can be used as characteristic markers for early gastric cancer diagnosis. The miR-101 is used for distinguishing the patients with gastric cancer before and after an operation, and can be used as a prognosis marker of the gastric cancer.

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

The invention provides a human tumor-related methylation site as well as a screening method and use thereof. The human tumor-related methylation site is selected from at least one methylation site on a human 18th chromosome, a human third chromosome and a human second chromosome; the change of methylation site, caused by BMI, on chromosomes is related to a human endometrial cancer; prognosis on a human tumor can be performed by detecting the methylation site changes on the chromosomes; the human tumor-related methylation site can be used as a potential prognosis marker of the tumor, and especially can be used as a prognosis marker of the human endometrial cancer.

The invention relates to a tumor image marker extraction method based on gene imaging. The invention provides a non-intrusive biomarker extraction method with high interpretability by adoption of the gene imaging and in combination with the advantages of the imaging and the molecular technology. According to the method, high-dimensional quantitative image features of a tumor CT are extracted and are associated with a corresponding tumor gene expression pattern; and it is assumed that some quantitative image features can reflect a specific gene expression pattern of a tumor and can be used as prognosis markers of the tumor. The ultimate goal is to extract a non-invasive and biologically interpretable imaging marker.

ROR2 is provided as a therapeutic target and prognostic marker for cancers, which include without limitation specific carcinomas and sarcomas. This invention also provides for the use of conjugates comprising an antibody that recognizes and binds ROR2, and a cytotoxic agent. In the cytotoxic conjugates, the cell binding agent has a high affinity for ROR2 and the cytotoxic agent has a high degree of cytotoxicity for cells expressing ROR2, such that the cytotoxic conjugates of the present invention form effective killing agents. In a preferred embodiment, the cell binding agent is an anti-ROR2 antibody or an epitope-binding fragment thereof, more preferably a humanized anti-ROR2 antibody or an epitope-binding fragment thereof, wherein a cytotoxic agent is covalently attached, directly or via a cleavable or non-cleavable linker, to the antibody or epitope-binding fragment thereof.

A method for predicting whether a patient suffering from a prostate cancer is at risk of experiencing a cancer progression or recurrence which comprises the steps of : obtaining a Gleason score of said prostate tumor sample; assessing the proportion of NF-kB localized in the nuclei of said tumor sample with regard to all NF-kB present in said tumor sample.

The invention provides a use of 2-hydroxyglutaric acid (2-HG) or a detection reagent thereof. A large amount of AML related mutant genes and cancer micro-molecular metabolites of blood system tumors and healthy examined people are screened to determine that the 2-HG can be used as an effective prognosis marker for effectively judging patients with blood system malignant tumors, especially AML, ALL and NHL. Additionally, the definition and the division of the abnormal rise of the 2-HG make the prognosis condition of like patients accurately determined in order to realize favorable guidance of clinic diagnosis and treatment.

A molecular marker for esophageal cancer is disclosed and is an FXR1 gene and/or an expression product of the FXR1 gene. The FXR1 gene is significantly highly expressed in esophageal cancer tissue, and can be adopted as an esophageal cancer molecular marker for esophageal cancer diagnosis. The highly expressed FXR1 gene is closely related to poor prognosis and distant metastasis of patients with esophageal cancer so that the FXR1 gene can be adopted as a prognosis marker for esophageal cancer and can provide effective information for esophageal cancer distant metastasis, prognosis evaluation and treatment effect monitoring. An expression inhibitor of the FXR1 gene is disclosed by the invention and includes siRNA and/or shRNA, has good jamming effects when being used for suppressing FXR1 gene expression and has a potential for application in clinical genetic treatment. The invention further discloses a cell strain capable of stable knock-down of the FXR1 gene. The cell strain is an esophageal cancer cell capable of stable low expression of the FXR1 gene, thus facilitating further research of functions of the FXR1 gene.

Pancreatic cancer is tumor with very poor prognosis and recognition of effective prognosis markers of the pancreatic cancer has great significance. The invention provides a method for assessing the prognosis risk of pancreatic cancer patients on the basis of a combined marker and a determining system of the method. The prognosis risk index is quantitatively calculated according to the expression condition of the combined marker in case samples, and layering of high and low risks of cases is performed. The invention relates to the combined marker consists of five proteins (the prognosis significance of CAPN2, DVL1 and FLNA among CAPN2, DVL1, FLNA, SHH and GLI1 for the pancreatic cancer is established for the first time), an immunohistochemical kit for detecting expression of the marker, a prognosis risk assessment and layering determining system and the like. Case implementation results in 280 and 120 cases of pancreatic cancer patients indicate that the combined marker can effectivelypredict prognosis risk of pancreatic cancer patients and has significant prediction effects on pancreatic cancer subgroup patients with high prognosis risk.

The invention belongs to the field of gene technology and medicine, in particular to C9orf139 and MIR600HG as prognostic markers of pancreatic cancer and an establishment method of the markers. The pancreatic cancer prognosis markers comprise C9orf139 and MIR600HG. By exploring the differentially-expressed mRNA, lncRNA and miRNA in pancreatic cancer, a ceRNA network is constructed to find new molecular screening biomarkers for pancreatic cancer and provide new analytical and molecular mechanisms for lncRNAs, miRNAs and pancreatic cancer mRNA. The invention determines two new biomarkers as potential pancreatic cancer prognosis indicators, and thus the prognosis of pancreatic cancer diseases is improved, and the accuracy of early diagnosis of pancreatic cancer is improved.

The invention belongs to the technical field of cell biology, and relates to application of Netrin-4 in preparing a preparation for detecting stomach cancer and a prognosis marker. Experiments display that Ntn4 is combined with a ligand neogenin thereof to activate cancer promoting paths such as Jak/Stat, PI3K/Akt and ERK/MAPK, thereby achieving the effects of promoting gastric cancer cell proliferation and invasion. Experiment results show that Ntn4 has remarkable high expression in both a serum sample and a tumor tissue sample of a patient with gastric cancer, high expression is in negative correlation with the lifetime of the patient and in positive correlation with TNM staging, it shows that Ntn4 can be used as potential serological indicator for gastric cancer and prognosis and used for preparing the preparation for detecting stomach cancer and the prognosis marker. The preparation comprises a reagent and a kit which are used for detecting stomach cancer and the prognosis marker.

The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer.

The invention belongs to the technical field of glioma prognosis markers, and particularly relates to application of BACE2 as a glioma prognosis/treatment marker. According to the invention, the research results prove that high-level BACE2 expression is related to the high-level human brain glioma, the mesenchymal molecule subtype of GBM and the poor prognosis for the first time; furthermore, TGF[beta] 1 stimulates BACE2 expression by means of Smad dependent signal transduction, so as to regulate the activity of TNF-[alpha] induced NF-[kappa] B by means of a PP1/IKK pathway to promote tumorigenesis in glioma cells. The BACE2 can be used as a novel biomarker and a potential treatment target for treating human brain glioma.

The present invention provides a diagnostic marker to detecting lung cancer. In particular, the present invention provides lung cancer marker genes i.e. KIF4A, MAPJD, NPTX, or FGFR1OP. The present invention further provides methods and kit for identifying compounds for treating lung cancer as well as methods for predicting a prognosis or diagnosis of lung cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between KIF4A/ZNF549, KIF4A/ZNF553, MAPJD/MYC, or FGFR1OP/WRNIP1 which find utility in the treatment and prevention of lung. Alternatively, the present invention provides MAPJD associated with HAT complex as therapeutic target.

The invention relates to an endometriosis canceration related ovarian cancer diagnostic or prognostic marker and application. Diagnosis and judgement of progression of disease of endometriosis canceration related ovarian cancer can be conducted according to the expression level of LncRNA BANCR of a body in eutopic endometrium. The LncRNA BANCR serves as the endometriosis canceration related ovarian cancer diagnostic or prognostic marker, and the LncRNA BANCR is applied to preparation of kits for diagnostic and/or prognostic assessment of endometriosis canceration related ovarian cancers. The LncRNA BANCR can serve as a novel biomarker for being used in diagnostic and/or prognostic assessment of the endometriosis canceration related ovarian cancers, and risk assessment of endometriosis canceration, and a chaff interferent corresponding to the LncRNA BANCR can serve as a novel drug, and has potential preventing and treating values to the endometriosis canceration related ovarian cancers.The endometriosis canceration related ovarian cancer diagnostic or prognostic marker can serve as the novel biomarker, and be applied to diagnostic and/or prognostic assessment of the endometriosis canceration related ovarian cancers, and has potential preventing and treating values to the endometriosis canceration related ovarian cancers.

The invention discloses an ovarian cancer drug-resistance marker UTP23, an expression ratio of an existing gene GDF15 and related prognosis of ovarian cancers. Particularly, when the ratio is low, anovarian cancer case shows poor prognosis according to prognostic indicators such as chemotherapy sensitivity, drug resistance, satisfactory cytoreductive surgery, progression free survival and overallsurvival. When the ratio is high, an ovarian cancer patient shows good prognosis, namely, clinical therapy of the ovarian cancers includes chemotherapy and surgical therapy to provide prognosis prompt.

The invention discloses a breast cancer prognosis evaluating marker and application, and belongs to the technical field of biology. The invention aims to find a marker for effectively evaluating breast cancer prognosis. TCGA, GEO and DNA methylation data of the whole genome level autonomously generated based on a sequencing technology are integrated, it is revealed that the tumor center is in a hypoxic state compared with the tumor edge, survival analysis finds that the HR of a CpG site cg15190451 is smaller than 1, it shows that the breast cancer progress risk is reduced along with increase of the methylation level, and the higher the level is, the patient prognosis is better; and it is prompted that the breast cancer prognosis effect can be judged according to the methylation level of the gene SLC16A5 where cg15190451 is located. The breast cancer prognostic marker is obtained by verifying hypoxia markers in an HER2 positive breast cancer sample on the basis of the expression level of SLC16A5, the breast cancer prognostic evaluation efficiency can be improved, the cost is saved, and the marker is suitable for popularization and application and has a good application prospect.